



Imaxio announces the publication of the results of a phase I trial of MVA85A-IMX313, the first human clinical trial using the IMX313 technology

The vaccine candidate has proven to be safe in healthy patients in this dose escalation study. These results confirm that IMX313, Imaxio's antigen re-engineering technology, is safe in humans

Lyon, France – March 17, 2016 – Imaxio, a biotech company specialized in immunology, announces today that the results of its tuberculosis vaccine phase I clinical trial have been published in the journal *Vaccine*. The trial, which was conducted by the Jenner Institute at Oxford University (UK), has proved that the vaccine candidate (and thus IMX313, Imaxio's antigen re-engineering technology) is safe in humans. The study was performed in the UK and was led by Prof. Helen McShane from the Jenner Institute at Oxford University. ¹

This phase I trial was a dose escalation study that aimed to assess the safety of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio's IMX313. Tuberculosis remains a significant cause of mortality and morbidity throughout the developing world. Indeed, the HIV epidemic and the emergence of multi-drug resistant strains of TB have made urgent the need for improved tuberculosis control.

"This clinical trial was the first administration of IMX313 in humans and has taught us a lot", explains Dr Fergal Hill, Chief Scientific Officer of Imaxio. "It confirms that our technology is safe in humans, therefore making us more confident in our pipeline of 5 IMX313-based vaccine candidates", adds Mr. Alexandre Le Vert, Chief Executive Officer of Imaxio.

"These results are encouraging, and we are pursuing with Imaxio our collaboration against tuberculosis", said Prof Helen McShane, Tuberculosis Program Leader and Professor of Vaccinology at the Jenner Institute at Oxford University.

About Imaxio SA

Imaxio is a small biotechnology company focused on immunology, with products ranging from commercial stage to clinical and preclinical R&D stages.

Its clinical-stage R&D pipeline is focused on vaccines for infectious diseases and immunotherapies in oncology. It includes five internal R&D projects plus seven active R&D collaborations, all based on a proprietary antigen re-engineering technology platform, called IMX313, which is designed to improve an antigen's immunogenicity. Using this technology, Imaxio works alongside several prominent international academic and industrial research teams to develop recombinant vaccines for infectious diseases (Influenza, Staphylococcus Aureus, Tuberculosis, Malaria) and oncology.

Imaxio also commercializes in France a human vaccine indicated for the prevention of an infectious occupational disease, called Spirolept®.

The company owns a solid IP portfolio and collaborates with numerous international partners, including the Jenner Institute at Oxford University (UK). Twelve of the twenty Imaxio employees are dedicated to R&D activities. In 2015 its turnover reached EUR 2 million. Imaxio is based in Lyon, France.

For further information: <http://www.imaxio.com>

About the Jenner Institute at Oxford University

The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. Uniquely it focuses both on diseases of humans and livestock and tests new vaccine approaches in parallel in different species. A major theme is translational research involving the rapid early-stage development and assessment of new vaccines in clinical trials.

The Institute comprises the research activities of over 28 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. Together the Institute investigators comprise one of the largest non-profit sector research and development activities in vaccinology.

The Institute is a partnership between the University of Oxford and The Pirbright Institute. The Institute is supported by the Jenner Vaccine Foundation, a UK registered charity, and advised by the Jenner Institute Scientific Advisory Board.

For further information, go to <http://www.jenner.ac.uk> and <http://www.jenner.ac.uk/transmission-blocking-vaccines>

For further information, please contact:

Imaxio S.A.

Raphaël METROP

rmetrop@imaxio.com

Tel: +33 437 655 506

1 – Minhinnick A et al, A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults, *Vaccine*, 2016 Feb 5, doi: 10.1016/j.vaccine.2016.01.062, <http://www.ncbi.nlm.nih.gov/pubmed/26854906>